GT Biopharma logo
GT Biopharma
GTBP | NASDAQ
Chart Builder DCF Calculator
$3.54
-$0.18 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
+$0.07 (+1.98%)
After-hours: Nov 16, 2026, 6:41 PM ET

GT Biopharma Company Profile

Company profile explained

Company Profile

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

Key Executives

Name Position
Michael Martin Breen President, CEO & Executive Chairman
Alan Louis Urban Chief Financial Officer & Secretary

Latest SEC Filings

Date Type Title
Oct 20, 2026 EFFECT Filing
Oct 20, 2026 424B3 Filing
Oct 13, 2026 DEF 14A Filing
Oct 09, 2026 S-1 Filing
Oct 02, 2026 PRE 14A Filing
Sep 29, 2026 D Filing
Sep 25, 2026 8-K Current Report
Sep 21, 2026 8-K Current Report
Sep 15, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 15, 2026 8-K Current Report
View All SEC Filings ➞
GT Biopharma
GT Biopharma logo
Country United States
IPO Date Mar 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Michael Martin Breen

Contact Details

315 Montgomery Street San Francisco, California 94104 United States

Stock Details

Ticker Symbol GTBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000109657
CUSIP Number 36254L407
ISIN Number US36254L4077
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.